Search research articles
Contact Us
Filters
Showing results (151-160 of 208) with videos related to
Page
of 21
Sort By:
The Oncologist
|
May 7, 2014
Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel
Douglas B Johnson, Kimberly H Dahlman, Jared Knol, et al.
The New England Journal of Medicine
|
August 20, 2015
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M Hyman, Igor Puzanov, Vivek Subbiah, et al.
Journal for Immunotherapy of Cancer
|
June 26, 2020
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
Yana G Najjar, Kristina Navrazhina, Fei Ding, et al.
Journal of Translational Medicine
|
June 7, 2022
Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021
Paolo A Ascierto, Antonio Avallone, Nina Bhardwaj, et al.
JAMA Oncology
|
December 4, 2015
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B Johnson, Ryan J Sullivan, Patrick A Ott, et al.
The New England Journal of Medicine
|
October 2, 2012
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Keith T Flaherty, Jeffery R Infante, Adil Daud, et al.
Nature Communications
|
January 30, 2016
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
Douglas B Johnson, Monica V Estrada, Roberto Salgado, et al.
Nature Communications
|
September 8, 2018
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
Qiuhui Li, Qu Deng, Hsueh-Ping Chao, et al.
Biorxiv : the Preprint Server for Biology
|
June 3, 2025
Increasing Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival
Xiaozhuo Liu, Eduardo Cortes, Yibing Ji, et al.
The New England Journal of Medicine
|
August 23, 2018
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A Tawbi, Peter A Forsyth, Alain Algazi, et al.
Page
of 21
Search research articles
Search
Showing results (151-160 of 208) with videos related to
Sort By:
Page
of 21
The Oncologist
|
May 7, 2014
Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel
Douglas B Johnson, Kimberly H Dahlman, Jared Knol, et al.
The New England Journal of Medicine
|
August 20, 2015
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M Hyman, Igor Puzanov, Vivek Subbiah, et al.
Journal for Immunotherapy of Cancer
|
June 26, 2020
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
Yana G Najjar, Kristina Navrazhina, Fei Ding, et al.
Journal of Translational Medicine
|
June 7, 2022
Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021
Paolo A Ascierto, Antonio Avallone, Nina Bhardwaj, et al.
JAMA Oncology
|
December 4, 2015
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B Johnson, Ryan J Sullivan, Patrick A Ott, et al.
The New England Journal of Medicine
|
October 2, 2012
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Keith T Flaherty, Jeffery R Infante, Adil Daud, et al.
Nature Communications
|
January 30, 2016
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
Douglas B Johnson, Monica V Estrada, Roberto Salgado, et al.
Nature Communications
|
September 8, 2018
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
Qiuhui Li, Qu Deng, Hsueh-Ping Chao, et al.
Biorxiv : the Preprint Server for Biology
|
June 3, 2025
Increasing Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival
Xiaozhuo Liu, Eduardo Cortes, Yibing Ji, et al.
The New England Journal of Medicine
|
August 23, 2018
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A Tawbi, Peter A Forsyth, Alain Algazi, et al.
Page
of 21